Sandoz Chief Warns 'Patients Pay the Tariff' on Generics

Sandoz chief executive Richard Saynor warned that steep U.S. tariffs on imported generic medicines, threatened by President Donald Trump, would force manufacturers either to raise prices or to withdraw supply, saying 'patients pay the tariff.'

The chief executive of one of the world's largest makers of copycat medicines has put a blunt label on Washington's tariff threat: whatever the policy intends, the bill lands on the sick. Sandoz CEO Richard Saynor warned that steep U.S. duties on imported generic drugs would leave manufacturers with two options and no good one — lift prices, or stop supplying the market. "Patients pay the tariff," he said, in comments reported by CNBC.

President Donald Trump has threatened tariffs on generic medicines as part of a broader push to pull pharmaceutical manufacturing back onto American soil. The branded side of the industry, with its fat gross margins and its long-dated pricing power, can absorb a border tax and argue about it later. The generics business cannot, and that asymmetry is the whole of Saynor's argument.

Why a tariff bites generics differently from branded drugs

Generic medicines are what the market gets after a patent expires: chemically identical products sold by multiple competing manufacturers, with price as effectively the only variable. That competition is the point — it is the mechanism by which a drug that once cost a fortune becomes a routine prescription — but it also means the economics are those of a commodity, not of an innovator.

In that structure, a cost shock has nowhere to hide. A branded manufacturer facing a new import duty can spread it across a product with a wide spread between manufacturing cost and list price. A generics supplier working on thin unit economics, bidding against rivals for pharmacy and wholesaler contracts, has no comparable cushion. Saynor's framing captures the mechanics precisely: the tariff does not get absorbed in the middle of the chain, because the middle of the chain has no room to absorb it. It moves forward to the payer and the patient, or the product simply goes away.

The second outcome is the one health systems should worry about more. Withdrawing a low-margin molecule from a single national market is a routine commercial decision for a global manufacturer, not a crisis. It becomes a crisis only afterward, when a drug that was cheap and abundant turns scarce and the remaining suppliers discover pricing power they did not previously have.

The supply chain the policy is aiming at

The tariff logic is straightforward on its face: tax imported medicine, and manufacturing relocates to the United States. The friction is in the timeline and in what exactly would need to move. Pharmaceutical production is not a single step. Active ingredients are synthesized in one place, formulated into finished doses in another, packaged and released in a third, and every one of those sites carries regulatory registrations tied to specific products. Redirecting that network is a multi-year capital project subject to inspection and approval, not a procurement decision.

That gap between the speed of a tariff and the speed of a factory is where the price increases and the supply exits live. A duty takes effect on a date. A qualified domestic production line does not. In the interval, the cost is real and the alternative capacity is not yet there — which is the sequence Saynor is describing when he says patients pay.

What manufacturers would actually do, in order

Faced with a border tax on low-margin products, a generics company has a fairly predictable decision tree, and it is worth spelling out because it explains why the damage would be uneven rather than uniform:

• Reprice where contracts allow it. Supply agreements with distributors and pharmacy benefit managers set what can be passed through and when. Where renegotiation is possible, price goes up.
• Reprioritize the portfolio. Global manufacturers allocate scarce production capacity across many markets. Products whose U.S. economics turn negative get deprioritized in favor of geographies where they still earn.
• Exit the marginal molecules. Older, heavily genericized, low-volume products — often the ones with the fewest alternative suppliers — are the first to be discontinued, because they contribute the least and cost the same to make.
• Invest domestically, eventually. Onshoring is the policy's intended endpoint, and some of it would happen. It is also the slowest of the four, which is why it does not solve the first three.

Note that the products most likely to disappear are not the ones with the most competition. They are the ones with the least — sterile injectables, older antibiotics, niche oncology supportive-care agents — precisely the categories where U.S. shortages have already been a recurring problem.

The market context around the warning

Saynor's comments arrive with equity markets in a constructive mood and showing little stress. At the most recent close on Friday, 11 September 2026, the S&P 500 tracker (NYSEARCA: SPY) finished at $764.29, up 0.85% on the day from a prior close of $757.83, with a session range of $763.60 to $766.38. The Nasdaq 100 fund (NASDAQ: QQQ) ended at $714.88, up 0.87%, and the Dow 30 vehicle (NYSEARCA: DIA) closed at $525.79, up 0.97%. Broad indexes, in other words, are not pricing a pharmaceutical supply shock.

That is normal, and it is not evidence that the warning is overstated. Generic medicines are a small share of U.S. healthcare spending relative to the volume of prescriptions they fill — cheapness is their defining feature — so the sector rarely moves an index. The consequences of a generics squeeze show up in hospital formularies and pharmacy back orders long before they show up in a benchmark chart.

What to watch from here

The first thing to watch is scope: whether any tariff carves out generics explicitly, applies a lower rate to them, or exempts products already on federal shortage lists. The difference between a blanket duty and a tiered one determines whether the threat is a negotiating posture or a cost event. The second is timing — whether implementation is phased over a window long enough for domestic capacity to be qualified, or imposed on a date that leaves manufacturers with only the repricing and exit levers.

The third is what other manufacturers say. Saynor has staked out a public position on behalf of a business whose entire value proposition is low cost. If peers across the generics and biosimilars industry echo the supply-withdrawal argument rather than the price-increase one, that is a signal the sector believes exit is the rational response — and that is the version of this policy that ends in shortages rather than in slightly higher copays.

Key facts

• Who: Richard Saynor, chief executive of Sandoz
• The warning: U.S. tariffs on imported generics would force price increases or supply cuts — 'Patients pay the tariff'
• Policy trigger: President Trump has threatened tariffs on imported generic drugs
• Market backdrop: S&P 500 tracker SPY closed at $764.29, +0.85%, as of Fri, 11 Sep 2026 20:00 GMT

Frequently asked questions

What did the Sandoz CEO actually say?

Richard Saynor, chief executive of Sandoz, warned that steep U.S. tariffs on imported generic drugs could force manufacturers either to raise prices or to cut supply to the American market. He summarized the effect with the phrase 'Patients pay the tariff,' arguing that low-margin generic producers have no room to absorb an import duty themselves.

Why can't generic drugmakers absorb a tariff?

Generic medicines are chemically identical to one another and compete almost entirely on price, which compresses margins to commodity levels. A branded drug with a wide gap between production cost and list price can absorb a new import duty; a generic sold on thin unit economics cannot. The cost therefore moves forward to payers and patients, or the product is withdrawn.

Which medicines would be most at risk of disappearing?

The products most exposed are typically older, low-volume, heavily genericized medicines that already have few suppliers — categories such as sterile injectables and older antibiotics. These contribute the least revenue but cost the same to manufacture, so they are the first candidates for discontinuation when a market's economics turn negative.

Would tariffs succeed in moving generic production to the United States?

Some onshoring would likely follow, but not quickly. Drug manufacturing is split across sites for active ingredients, formulation and packaging, each carrying product-specific regulatory registrations. Building and qualifying domestic capacity is a multi-year process requiring inspection and approval, while a tariff takes effect on a set date — leaving a gap in which costs are real and replacement capacity is not.

How did markets react to the warning?

Broad indexes showed no visible stress. At the most recent close on Friday, 11 September 2026, the S&P 500 tracker SPY ended at $764.29, up 0.85%; the Nasdaq 100 fund QQQ closed at $714.88, up 0.87%; and the Dow 30 vehicle DIA finished at $525.79, up 0.97%. Generics are cheap by design and rarely move benchmark indexes.

What should observers watch next on this policy?

Three things: whether any tariff carves out generic medicines or applies a reduced rate to them; whether implementation is phased over enough time for domestic manufacturing to be qualified; and whether other generics and biosimilar manufacturers echo the supply-withdrawal argument rather than the price-increase one, which would signal that exit is the industry's rational response.

Sources

• 'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat — CNBC Health

Photo: Castorly Stock · Pexels Licence — source